Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of fufang-like anti-fibrotic agent fluorfenidone capsules added to tenofovir alafenamide for chronic hepatitis B liver fibrosis/cirrhosis
CTR20262153Phase 3Active
- Sponsor
- Haikou Pharmaceutical Factory Co., Ltd.
- Start
- Sep 2026
- Countries
- 1
01
Overview
A Phase 3 trial of fluorfenidone in hepatic fibrosis, Cirrhosis, Chronic Hepatitis B (CHB), sponsored by Haikou Pharmaceutical Factory Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
fluorfenidone
03
Conditions
hepatic fibrosisCirrhosisChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20262153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262153.